Core Viewpoint - The semi-annual report of Jiaying Pharmaceutical for 2025 demonstrates strong internal growth and operational capabilities, achieving a revenue of 199 million yuan, a year-on-year increase of 10.40%, and a net profit of 20.08 million yuan, a remarkable growth of 254.33% [3] Group 1: Profitability Enhancement - Jiaying Pharmaceutical's significant net profit growth is attributed to strategic collaboration and refined operations rather than just revenue expansion [4] - The company has implemented lean management and optimized production and sales coordination, leading to improved production efficiency [4] - The cost of goods sold decreased by 5.52%, while gross margin increased to 62.53%, reflecting enhanced profitability and operational quality [4] Group 2: Product Structure Optimization - The company has focused on optimizing its product structure, increasing the sales proportion of high-margin products, which has significantly boosted overall profitability [5] Group 3: Innovation and R&D - Jiaying Pharmaceutical is transitioning from a traditional Chinese medicine manufacturer to a research-driven enterprise, with R&D investment reaching 4.81 million yuan, a 15.95% increase [6] - The company is developing a new drug targeting rheumatoid arthritis, which is expected to become a key product upon completion of clinical trials [6][7] - Collaborative projects with other companies have expanded the product pipeline while maintaining a "light asset R&D" model to control risks [7] Group 4: Strategic Transformation - The company is accelerating its transformation towards a modern, international pharmaceutical enterprise, establishing a wholly-owned subsidiary in Hong Kong for international trade [8] - Jiaying Pharmaceutical has invested in a health technology company, marking its entry into the digital health sector [8] - The company has adopted a dual-channel strategy to enhance market penetration and brand value, ensuring competitiveness in a changing market landscape [9] Group 5: Summary - The semi-annual report reflects not only a surge in performance but also a significant step in the company's strategic transformation towards high-quality development amidst industry changes [10]

Core Viewpoint - The semi-annual report of Jiaying Pharmaceutical for 2025 demonstrates strong internal growth and operational capabilities, with revenue increasing by 10.40% to 199 million yuan and net profit soaring by 254.33% to 20.08 million yuan, amidst a challenging pharmaceutical industry environment [1][2]. Financial Performance - Jiaying Pharmaceutical achieved a revenue of 199 million yuan in the first half of 2025, reflecting a year-on-year growth of 10.40% [1][2]. - The company's net profit reached 20.08 million yuan, marking a significant increase of 254.33% compared to the previous year [1]. - Operating costs decreased by 5.52%, leading to a gross profit margin increase to 62.53%, up by 6.33 percentage points [2]. Operational Efficiency - The company has implemented lean management and optimized production and sales coordination, enhancing overall production efficiency through automation and intelligent production lines [2]. - A systematic overhaul of raw material procurement strategies has strengthened supply chain cost control, effectively reducing production costs [2]. - Continuous improvement of the quality management system has been emphasized, with multiple GMP training sessions conducted to ensure compliance and enhance product quality [2]. Product Strategy - Jiaying Pharmaceutical is optimizing its product structure by increasing the sales proportion of high-margin products, with flagship products like Shuangliao Houfeng San and Zhonggan Ling Pian achieving significant sales growth [3]. Innovation and R&D - The company invested 4.81 million yuan in R&D during the first half of 2025, a year-on-year increase of 15.95%, supporting its transition to a research-driven enterprise [4][5]. - A new drug targeting rheumatoid arthritis, developed in collaboration with Hunan University of Traditional Chinese Medicine, has completed Phase II clinical trials and is expected to enter Phase III trials by the end of the year [4]. - Jiaying Pharmaceutical is pursuing a dual approach of "independent R&D + collaborative development" to enhance R&D efficiency and accelerate the transformation of research outcomes [5]. Strategic Transformation - The company is advancing its transformation from a traditional Chinese medicine manufacturer to a modern, international pharmaceutical enterprise [6]. - Jiaying Pharmaceutical established a wholly-owned subsidiary in Hong Kong to facilitate international trade and enhance procurement and export efficiency [7]. - The company is also venturing into the digital health sector by investing in a health technology company, aiming to leverage e-commerce and internet healthcare trends [7]. Brand Development - Jiaying Pharmaceutical's brand "Jiaying" was recognized as one of the first Guangdong Time-honored Brands in 2024, enhancing its brand value and product premium capabilities [8]. Conclusion - The semi-annual report of Jiaying Pharmaceutical not only reflects a significant performance surge but also marks a milestone in the company's strategic transformation towards high-quality development in a rapidly evolving industry landscape [9].

Group 1: Company Performance - Jia Ying Pharmaceutical reported a net profit of 20.08 million yuan for the first half of 2025, a year-on-year increase of 254.33% [1] - Aote Xun recorded a net loss of 28.97 million yuan for the first half of 2025, compared to a loss of 17.45 million yuan in the same period last year [1] - China Ruilin achieved a net profit of 74.75 million yuan, reflecting a year-on-year growth of 26.77% [1] - Shanxi Coking experienced a net loss of 77.61 million yuan, reversing from a profit of 184 million yuan in the previous year [3] - Dazhu Laser reported a net profit of 488 million yuan, a decline of 60.15% year-on-year [5] - Jin Zi Tian Zheng achieved a net profit of 21.66 million yuan, a year-on-year increase of 17.59% [7] - Bao Tai Long turned a profit with a net profit of 98.88 million yuan, compared to a loss of 192 million yuan in the previous year [9] - Qujiang Cultural Tourism reported a net loss of 13.88 million yuan, compared to a loss of 187 million yuan in the same period last year [9] - New Yisheng reported a net profit of 3.94 billion yuan, a year-on-year increase of 355.68% [11] - Blue Si Technology achieved a net profit of 1.14 billion yuan, reflecting a year-on-year growth of 32.68% [12] - Huichuan Technology reported a net profit of 2.97 billion yuan, a year-on-year increase of 40.15% [13] - Ju Yi Technology achieved a net profit of 39.79 million yuan, a year-on-year increase of 69.48% [15] - Ke Ma Technology reported a net profit of 172 million yuan, a year-on-year increase of 23.52% [22] Group 2: Company Announcements - ST Quan Wei's subsidiary signed a contract for a photovoltaic project worth approximately 1.125 billion yuan [10] - ST Ya Lian announced that its stock will be delisted from risk warnings starting August 27, 2025 [16] - Yang Fan New Materials announced that its controlling shareholder is under investigation [18] - Sairun Bio's rabies serum product has started sales in several provinces [20] - Hengsheng Electronics announced that a director plans to reduce holdings by up to 8 million shares [21] - Beijing Junzheng plans to issue H-shares and list on the Hong Kong Stock Exchange [21] - Guo An Da intends to invest 104 million yuan to gain control of Ke Wei Tai [22] - Ke Ma Technology plans to issue convertible bonds to raise up to 750 million yuan [23]

Summary of Key Points Core Viewpoint - In August 2023, a total of 673 companies released their semi-annual reports for 2025, with 353 companies reporting a year-on-year increase in net profit, while 320 reported a decline. Additionally, 389 companies saw an increase in operating revenue, and 284 experienced a decrease. Notably, 255 companies had both net profit and operating revenue growth, while 186 companies reported declines in both metrics. The company with the highest profit growth was Huahong Technology, with an increase of 3480.57% [1]. Group 1: Company Performance - Huahong Technology reported a net profit of 79.63 million yuan, with a staggering year-on-year increase of 3480.57% and operating revenue of 315.94 million yuan, up 17.17% [1]. - Other notable performers include: - Guangda Tongchuang with a net profit of 23.22 million yuan, a year-on-year increase of 2699.69%, and operating revenue of 74.99 million yuan, up 48.31% [1]. - Qiming Information reported a net profit of 14.19 million yuan, up 2568.50%, with operating revenue of 32.99 million yuan, an increase of 6.51% [1]. - New Yisheng achieved a net profit of 394.23 million yuan, a 355.68% increase, with operating revenue of 1,043.72 million yuan, up 282.64% [1]. Group 2: Revenue Trends - A total of 71 companies experienced a doubling of their performance metrics, indicating strong growth potential in the market [1]. - The overall trend shows that while many companies are experiencing growth, there are also significant numbers reporting declines, highlighting a mixed performance landscape [1]. - Companies like Huafeng Technology and Yongding Co. also reported substantial increases in both net profit and operating revenue, with year-on-year growth rates of 940.64% and 917.66%, respectively [1].

Group 1 - The core viewpoint of the announcement is that the Supervisory Board of Guangdong Jiaying Pharmaceutical Co., Ltd. has confirmed the authenticity and completeness of the company's 2025 semi-annual report and its summary, stating there are no false records or misleading statements [1][2]. - The Supervisory Board meeting was held on August 14, 2025, with all three attending supervisors present, and the meeting was conducted in accordance with legal and regulatory requirements [1]. - The voting results of the Supervisory Board were unanimous, with 3 votes in favor, 0 against, and 0 abstentions, indicating strong agreement on the report's accuracy [1]. Group 2 - The company disclosed the 2025 semi-annual report and its summary on the same day through the Giant Tide Information Network [1]. - The meeting was chaired by Mr. Zhong Gaohua, and some senior management personnel attended as observers [1]. - The Supervisory Board's decision reflects a commitment to transparency and accountability in financial reporting [1].

截至发稿，嘉应制药市值为34亿元。 （记者 张喜威） 每经AI快讯，嘉应制药（SZ 002198，收盘价：6.76元）8月25日晚间发布公告称，公司第七届第九次董 事会会议于2025年8月25日在嘉应制药（湖南）有限公司会议室以现场结合通讯方式召开。会议审议了 《关于公司<2025年半年度报告>及其摘要的议案》等文件。 每经头条（nbdtoutiao）——租下2.5万亩"试验田"，兽医学博士在非洲种粮：首季亩产250斤，打算扩至 10万亩，月薪1~2万元招人 2024年1至12月份，嘉应制药的营业收入构成为：医药行业占比99.8%，其他业务占比0.2%。 ...

格隆汇8月25日丨嘉应制药(002198.SZ)公布2025年半年度报告，上半年公司实现营业收入1.99亿元，同 比增长10.40%；归属于上市公司股东的净利润2008.26万元，同比增长254.33%；归属于上市公司股东的 扣除非经常性损益的净利润1878.86万元，同比增长1,516.06%；基本每股收益0.0396元。 ...

人民财讯8月25日电，嘉应制药(002198)8月25日晚间披露2025年半年报，上半年实现营业收入1.99亿 元，同比增长10.4％；归母净利润2008.26万元，同比增长254.33%；基本每股收益0.0396元。 转自：证券时报 ...

上市公司2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：广东嘉应制药股份有限公司 单位：人民币万元 注：①表中非经营性占用部分，关联方范围依照《股票上市规则》确定。 ②无控股股东、实际控制人的公司，存在第一大股东或第一大股东关联人非经营性占用资金的，也应填写本表非经营性占用部分。 | 非经营性资金占用 | 资金占 用方名称 | 占用方与上 市公司的关联 关系 | 上市公司核 算的会计科 目 | 年半年 2025 度期初占用 资金余额 | 2025 息） | 年半年度 占用累计发生 金额（不含利 | 2025 年半年 度占用资金的 利 息（如有） | 2025 年半年 度偿还累计发 生 金额 | 年半年 2025 度期末占用资 金余额 | 占用形 成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股股东、实际控制人及 | | | | | | | | | | | 非经营性占 | | 其附属企业 | | | | | | | | | | | 用 | | 小计 | - ...

广东嘉应制药股份有公司 2025 年半年度财务报告 （未经审计） 2025 年 8 月 1 财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：广东嘉应制药股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 201,259,933.75 | 336,141,154.38 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 4,793,858.00 | | | 衍生金融资产 | | | | 应收票据 | 15,167,699.94 | 29,457,997.77 | | 应收账款 | 137,011,253.22 | 76,991,474.27 | | 应收款项融资 | 5,386,262.85 | 22,477,878.29 | | 预付款项 | 8,501,725.31 | 1,634,160.12 | | 应收保费 | | | | 应收分 ...